Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy

被引:14
作者
Poole, Chris D. [1 ]
Bannister, Christian A. [1 ]
Andreasen, Jakob Norgaard [2 ]
Andersen, Jens Strodl [2 ]
Currie, Craig J. [1 ]
机构
[1] Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales
[2] ALK, Horsholm, Denmark
基金
英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; RHINITIS; CONJUNCTIVITIS; PREVALENCE; SEVERITY; TABLETS; BURDEN; MODELS; IMPACT; COST;
D O I
10.1186/1477-7525-12-99
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis (ARC) but its impact on general health-related utility has not been characterised for the purposes of economic evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass immunotherapy tablet (GRAZAX (R), 75,000 SQ-T/2,800 BAU, ALK, Denmark). Methods: Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of GRAZAX (R). Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and medication use. Results: DSS and DMS were the principal predictors of 'perfect' health (EQ-5D = 1.000; binomial) and 'imperfect' health (EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of 'perfect' health (EQ-5D = 1.000) by 27% and 16% respectively, and reduced 'imperfect' health by 0.17 and 0.13, respectively. Gender remained the only other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX (R) was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX (R) = 0.938 units (95% CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period. Conclusions: ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs observed for GRAZAX (R) may not fully describe the health benefits of this treatment, suggesting that economic modelling may be conservative.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample
    Wu, Mengjun
    Brazier, John E.
    Kearns, Benjamin
    Relton, Clare
    Smith, Christine
    Cooper, Cindy L.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (02) : 141 - 151
  • [42] Effect of impairment on health-related quality of life in people with multiple sclerosis: association of functional systems and EQ-5D-5L index values in a cross-sectional study
    Schmidt, Richard
    Starke, Andreas
    Bednarz, Natalie
    Bergh, Florian Then
    QUALITY OF LIFE RESEARCH, 2025, : 1773 - 1781
  • [43] Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures
    Hazel Hayhurst
    Stephen Palmer
    Rosemary Abbott
    Tony Johnson
    Jan Scott
    Quality of Life Research, 2006, 15 : 1271 - 1280
  • [44] Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures
    Hayhurst, Hazel
    Palmer, Stephen
    Abbott, Rosemary
    Johnson, Tony
    Scott, Jan
    QUALITY OF LIFE RESEARCH, 2006, 15 (07) : 1271 - 1280
  • [45] Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
    Limone, Brendan L.
    Sidovar, Matthew F.
    Coleman, Craig I.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [46] Measuring health-related quality of life in women with endometriosis: comparing the clinimetric properties of the Endometriosis Health Profile-5 (EHP-5) and the EuroQol-5D (EQ-5D)
    Aubry, G.
    Panel, P.
    Thiollier, G.
    Huchon, C.
    Fauconnier, A.
    HUMAN REPRODUCTION, 2017, 32 (06) : 1258 - 1269
  • [47] Evaluating the Health-Related Quality of Life of the Rare Disease Population in Hong Kong Using EQ-5D 3-Level
    Ng, Yvette N. C.
    Ng, Nicole Y. T.
    Fung, Jasmine L. F.
    Lui, Adrian C. Y.
    Cheung, Nicholas Y. C.
    Wong, Wilfred H. S.
    Lee, So Lun
    Knapp, Martin
    Chung, Claudia C. Y.
    Chung, Brian H. Y.
    VALUE IN HEALTH, 2022, 25 (09) : 1624 - 1633
  • [48] Examining the association between menstrual symptoms and health-related quality of life among working women in Japan using the EQ-5D
    Shimamoto, Kyoko
    Hirano, Mana
    Wada-Hiraike, Osamu
    Goto, Rei
    Osuga, Yutaka
    BMC WOMENS HEALTH, 2021, 21 (01)
  • [49] An assessment of the impact of informative dropout and nonresponse in measuring health-related quality of life using the EuroQol (EQ-5D) descriptive system
    Ratcliffe, J
    Young, T
    Longworth, L
    Buxton, M
    VALUE IN HEALTH, 2005, 8 (01) : 53 - 58
  • [50] The impact of 29 chronic conditions on health-related quality of life:: A general population survey in finland using 15D and EQ-5D
    Saarni, Samuli I.
    Harkanen, Tommi
    Sintonen, Harri
    Suvisaari, Jaana
    Koskinen, Seppo
    Aromaa, Arpo
    Lonnqvist, Jouko
    QUALITY OF LIFE RESEARCH, 2006, 15 (08) : 1403 - 1414